About Us

The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.

We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.

Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.

JDD reaches around 13,760 dermatology healthcare professionals and has been recognized as the official partner of the Skin of Color Update (SOCU) and the ODAC Dermatology Aesthetic and Surgical (ODAC) conferences.

The extremely current and practical editorial content of JDD results in high readership and maximum exposure among the dermatology community.

Our Mission is Excellence through Peer Review: To educate physicians, optimize patient outcomes, and disseminate key scientific information.

JDD is published by SanovaWorks.

In the News

October 27, 2026 in Featured Articles, Hidradenitis Suppurativa, JDD in the Media, Latest News

Hot Topics in the JDD: Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) treatment has drastically changed in the last 15 years with FDA-approved biologics and an understanding of the need for comprehensive care that addresses the multifactorial pathogenesis of…
Read More
October 21, 2026 in Featured Articles, JDD in the Media, Latest News

ICYMI: Most Popular Articles From the Summer JDD

Leaves are falling and nights are getting longer — fall is here. Even if summer felt like it went by in a blink, it's important not to miss developments in…
Read More
October 5, 2026 in Featured Articles, JDD in the Media, Latest News

JDD in the News: JDD in the News: Dermatology Clinician Perspectives on Sunscreen

The August issue of Dermatology Times featured an article written by dermatologist Darrell Rigel, MD, FAAD, about his 2025 Journal of Drugs in Dermatology study on dermatology clinician perspectives on…
Read More
September 2, 2026 in Featured Articles, JDD in the Media, Latest News

JDD in the News: UV Light as a Workplace Hazard

Healio featured two Journal of Drugs in Dermatology studies in recent articles, including an article on UV light as an underappreciated workplace hazard. The study, "Sun Exposure and Cancer Outcomes…
Read More
July 27, 2026 in Featured Articles, JDD in the Media, Latest News

JDD in the News: Ruxolitinib vs. Triamcinolone for Atopic Dermatitis

MedPage Today/Dermatology World Weekly highlighted a Journal of Drugs in Dermatology study comparing a topical JAK inhibitor with a common topical steroid in atopic dermatitis (AD). The study, “Ruxolitinib Cream…
Read More

Editorial Board

Founder
Perry Robins, MD

Editor-in-Chief
Deborah S. Sarnoff MD